Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Rating) – Stock analysts at SVB Leerink reduced their Q2 2022 earnings per share estimates for shares of Xeris Biopharma in a research note issued on Wednesday, May 11th. SVB Leerink analyst R. Ruiz now forecasts that the company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.21). SVB Leerink has a “Outperform” rating and a $6.00 price objective on the stock. SVB Leerink also issued estimates for Xeris Biopharma’s Q3 2022 earnings at ($0.23) EPS, Q4 2022 earnings at ($0.25) EPS, FY2022 earnings at ($0.95) EPS, FY2023 earnings at ($0.65) EPS and FY2025 earnings at ($0.15) EPS.
Several other analysts also recently issued reports on XERS. Craig Hallum began coverage on Xeris Biopharma in a report on Thursday, April 28th. They set a “buy” rating and a $6.50 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price (down previously from $8.00) on shares of Xeris Biopharma in a report on Friday, March 11th. Mizuho dropped their target price on Xeris Biopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, March 16th. Finally, Zacks Investment Research downgraded Xeris Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, January 20th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $6.13.
Xeris Biopharma (NASDAQ:XERS – Get Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.21). Xeris Biopharma had a negative return on equity of 258.57% and a negative net margin of 217.81%. The business had revenue of $21.43 million during the quarter, compared to the consensus estimate of $20.72 million. During the same quarter last year, the firm posted ($0.41) earnings per share.
In other Xeris Biopharma news, insider Paul R. Edick purchased 100,000 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was bought at an average cost of $1.40 per share, for a total transaction of $140,000.00. Following the completion of the acquisition, the insider now directly owns 1,508,064 shares in the company, valued at $2,111,289.60. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Steven Prestrelski sold 11,228 shares of the company’s stock in a transaction that occurred on Tuesday, February 22nd. The stock was sold at an average price of $2.42, for a total value of $27,171.76. The disclosure for this sale can be found here. 4.01% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP raised its stake in shares of Xeris Biopharma by 5.4% in the first quarter. GSA Capital Partners LLP now owns 117,307 shares of the company’s stock valued at $300,000 after purchasing an additional 6,035 shares in the last quarter. Cetera Advisor Networks LLC raised its stake in shares of Xeris Biopharma by 7.4% in the first quarter. Cetera Advisor Networks LLC now owns 91,656 shares of the company’s stock valued at $235,000 after purchasing an additional 6,281 shares in the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Xeris Biopharma in the first quarter valued at $71,000. IHT Wealth Management LLC raised its stake in Xeris Biopharma by 2.6% during the fourth quarter. IHT Wealth Management LLC now owns 342,897 shares of the company’s stock worth $1,005,000 after acquiring an additional 8,530 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Xeris Biopharma by 186.5% during the fourth quarter. JPMorgan Chase & Co. now owns 13,257 shares of the company’s stock worth $39,000 after acquiring an additional 8,629 shares in the last quarter. Institutional investors own 18.72% of the company’s stock.
About Xeris Biopharma (Get Rating)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
- Get a free copy of the StockNews.com research report on Xeris Biopharma (XERS)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.